Best strategies for hypertension management in type 2 diabetes and obesity

Current Diabetes Reports

Volumn 10, Issue 2, 2010, Pages 139-144

  Allcock, Darren M ^a   Sowers, James R ^a  

^a University of Missouri   (United States)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Hypertension; Type 2 diabetes mellitus

Indexed keywords

ALISKIREN; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM ANTAGONIST; CAPTOPRIL; CARVEDILOL; CLONIDINE; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROCHLOROTHIAZIDE; NEBIVOLOL; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ANGIONEUROTIC EDEMA; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; COUGHING; DEHYDRATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK REDUCTION; COMPLICATION; MOTIVATION;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; GOALS; HUMANS; HYPERTENSION; OBESITY;

EID: 77953618084     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0100-z     Document Type: Review

References (30)

1. Mathew J, Sleight P, Lonn E, et al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104:1615-1621.
2. Sowers JR, Bakris GL: ASH position paper: treatment of hypertension in patients with diabetes - an update. J Clin Hypertens 2008, 10:707-713.
3. Chaturvedi N, Sjolie AK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998, 351:28-31.
4. Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882-1885.
5. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999, 353:611-616. (Pubitemid 29087980)
6. Barzilay JI, Davis BR, Cutler JA, et al.: Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006, 166:2191-2201.
7. Wing LM, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2002, 348:583-592.
8. Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
9. Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
10. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
11. Lindholm LH, Hansson L, Ekbom T, et al.: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 2000, 18:1671-1675.
12. Beckett NS, Peters R, Fletcher AE, et al.: Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358:1887-1898.
13. Ernst ME, Carter BL, Goerdt CJ, et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-358.
14. UK Prospective Diabetes Study Group: Efficacy of atenolol ad captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-720.
15. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010. (Pubitemid 34286537)
16. Pessina AC, Ciccariello L, Perrone F, et al.: Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 2006, 16:137-147.
17. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 286:1967-1975.
18. Hillebrand U, Lang D, Telgmann RG, et al.: Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study. J Hypertens 2009, 27:517-526.
19. Khakam Z, Yasmin, McEniery CM, et al.: A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008, 26:351-356.
20. Bakris GL, Copley JB, Vicknair N, et al.: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM-associated nephropathy. Kidney Int 1996, 50:1641-1650.
21. Jamerson K, Weber MA, Bakris GL, et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
22. Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719-2728.
23. Sowers JR, Whaley-Connell A, Epstein M: Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-783.
24. Lane DA, Shah S, Beevers DG: Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007, 25:891-894.
25. Schmieder RE, Philipp T, Guerediaga J, et al.: Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009, 27:1493-1501.
26. Schmieder RE, Philipp T, Guerediaga J, et al.: Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009, 119:417-425.
27. Solomon SD, Appelbaum E, Manning WJ, et al.: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530-537.
28. Yamamoto E, Kataoka K, Dong Y-F, et al.: Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009, 54:633-638.
29. Weber MA, Black H, Bakris G, et al.: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1423-1431.
30. Takenouchi Y, Kobayashi T, Matsumoto T, et al.: Possible involvement of Akt activity in endothelial dysfunction in type 2 diabetic mice. J Pharmacol Sci 2008, 106:600-608.